Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
April 24, 2023
- Drug Makers’ New Grad Hiring in Japan Up 5.8%, Rising for 1st Time since FY2020
April 21, 2023
- Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Lonsurf-Bevacizumab Combo Gets FDA’s Priority Review in Colorectal Cancer: Taiho
April 20, 2023
- Ono Aims Higher with Aggressive Open Innovation in Drug Discovery
April 19, 2023
- Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
- Nobelpharma Sues Sawai over Nobelzin Patent in Japan
April 19, 2023
- Over 40,000 Patients Given Xocova as of April 9: Shionogi
April 18, 2023
- Rexulti Backed by FDA Advisors for Alzheimer’s Agitation: Otsuka/Lundbeck
April 18, 2023
- Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
April 18, 2023
- BMS Seeks 3rd Line MM Use for Abecma in Japan
April 18, 2023
- FDA OKs Nippon Shinyaku’s PII Plan for Exon 44-Directed DMD Drug
April 17, 2023
- Upsher-Smith Launches Combigan Generic in US: Sawai
April 17, 2023
- iPark Institute Takes Over Shonan iPark Operations from Takeda to Boost Neutrality, Collaborations
April 14, 2023
- Sawai Moved Ahead with WPP Rate Hikes for Generics amid Tough Biz Environment
April 14, 2023
- Chugai, TWOCELLS End Knee Chondrogenesis Cell Therapy Deal
April 14, 2023
- Kaken Aborts ART-648 Program, Incurring 1.5 Billion Yen Impairment Loss
April 14, 2023
- AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
- Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
April 13, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…